ULTOMIRIS
ULTOMIRIS (ravulizumab-cwvz) is a monoclonal antibody that helps the body’s immune system by targeting and destroying certain cells, helping to protect healthy cells from damage.
ULTOMIRIS is used to treat adults with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare genetic disorder in which defective red blood cells break down prematurely and leak hemoglobin into the blood. ULTOMIRIS is also used to treat adults and children 1 month of age and older with a disease called atypical Hemolytic Uremic Syndrome (aHUS).
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
What it treats
Paroxysmal Nocturnal Hemoglobinuria (PNH)
in adults & Atypical Hemolytic Uremic
Syndrome (aHUS) in adults and children one
month of age or older
Prescribed by
Hematologists or other prescribers specifically enrolled in the Ultomiris REMS program
How it’s administered
Intravenous (IV) infusion
Frequency
Every eight weeks, starting two weeks after an initial loading dose
Length of treatment
Usually about two hours in adults &
up to four hours in children